NASDAQ:EIGR   Eiger BioPharmaceuticals, Inc
X-B is retrace is slightly over target. That said this has an average analyst target of $34.17. It looks like it will be dropping for a little bit. So wait on entry

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.